MarketCap
Facebook
X
TelegramQuarterly report 2022-Q2
added 08-09-2022
Epizyme Cash and Cash Equivalents 2011-2025 | EPZM
Annual Cash and Cash Equivalents Epizyme
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 98.3 M | 168 M | 139 M | 86.7 M | 227 M | 77.9 M | 208 M | 190 M | 124 M | 98 M | 33.3 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 227 M | 33.3 M | 132 M |
Quarterly Cash and Cash Equivalents Epizyme
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 71.1 M | 77.4 M | 98.3 M | 125 M | 80.2 M | 73.7 M | 168 M | 168 M | 168 M | 168 M | 139 M | 139 M | 139 M | 139 M | 86.7 M | 86.7 M | 86.7 M | 86.7 M | 227 M | 227 M | 227 M | 227 M | 77.9 M | 77.9 M | 77.9 M | 77.9 M | 208 M | 208 M | 208 M | 208 M | 190 M | 190 M | 190 M | 190 M | 124 M | 124 M | 124 M | 124 M | 98 M | 98 M | 98 M | - | 33.3 M | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 227 M | 33.3 M | 137 M |
Cash and Cash Equivalents of other stocks in the Biotechnology industry
| Issuer | Cash and Cash Equivalents | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
ARCA biopharma
ABIO
|
61.6 M | - | 1052.0 % | $ 415 M |  USA |
 |
Alpine Immune Sciences
ALPN
|
13.4 M | - | - | $ 2.17 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
26.3 M | $ 4.75 | 1.61 % | $ 788 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
24.6 M | $ 3.29 | -2.08 % | $ 254 M | USA |
 |
AlloVir
ALVR
|
118 M | - | 4.14 % | $ 49.1 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
152 M | $ 25.32 | -2.24 % | $ 1.23 B | USA |
 |
Acasti Pharma
ACST
|
22.1 M | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
144 M | - | -15.15 % | $ 60.3 M |  Britain |
 |
Ampio Pharmaceuticals
AMPE
|
4.09 M | - | -11.43 % | $ 502 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
89.4 M | - | - | $ 1.01 B | USA |
 |
Ascendis Pharma A/S
ASND
|
560 M | $ 209.8 | -0.17 % | $ 5 B |  Danmark |
 |
Albireo Pharma
ALBO
|
248 M | - | -0.23 % | $ 916 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
2.41 M | - | - | $ 7.46 M |  Israel |
 |
Aptorum Group Limited
APM
|
3.5 M | $ 1.31 | -1.88 % | $ 7.14 M |  China |
 |
Alterity Therapeutics Limited
ATHE
|
34.8 M | $ 3.34 | -2.47 % | $ 8.04 B |  Australia |
 |
AstraZeneca PLC
AZN
|
5.49 B | $ 89.69 | -0.67 % | $ 96.9 B | Britain |
 |
Anika Therapeutics
ANIK
|
72.9 M | $ 9.55 | 0.58 % | $ 140 M | USA |
 |
Brickell Biotech
BBI
|
10.9 M | - | -5.38 % | $ 6.06 M | USA |
 |
BeiGene, Ltd.
BGNE
|
2.63 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bellicum Pharmaceuticals
BLCM
|
21.8 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
86.5 M | - | -7.31 % | $ 87 M | USA |
 |
Benitec Biopharma
BNTC
|
97.7 M | $ 12.34 | -4.78 % | $ 508 M | USA |
 |
Aytu BioScience
AYTU
|
31 M | $ 2.35 | 3.0 % | $ 14.8 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
220 M | - | -6.81 % | $ 3.04 B | USA |
 |
Baudax Bio
BXRX
|
5.26 M | - | 0.59 % | $ 63 K | USA |
 |
Avenue Therapeutics
ATXI
|
2.59 M | - | -52.27 % | $ 4.45 M | USA |
 |
ChromaDex Corporation
CDXC
|
44.5 M | - | -0.88 % | $ 598 M | USA |
 |
Axon Enterprise
AXON
|
455 M | $ 568.91 | -2.09 % | $ 43.1 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
8.27 M | $ 0.28 | -2.28 % | $ 609 M | Israel |
 |
Catalyst Biosciences
CBIO
|
33.5 M | $ 14.62 | -4.54 % | $ 962 M | USA |
 |
Cerus Corporation
CERS
|
20.3 M | $ 2.19 | 1.63 % | $ 404 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
6.6 M | - | - | $ 169 M | USA |
 |
Caladrius Biosciences
CLBS
|
16.2 M | - | -16.75 % | $ 25.8 M | USA |
 |
Clovis Oncology
CLVS
|
143 M | - | -7.23 % | $ 13 M | USA |
 |
Biogen
BIIB
|
2.38 B | $ 174.71 | 1.28 % | $ 25.4 B | USA |
 |
BioVie
BIVI
|
17.5 M | $ 1.46 | -3.61 % | $ 2.16 M | USA |
 |
Celldex Therapeutics
CLDX
|
28.4 M | $ 27.71 | -0.82 % | $ 1.78 M | USA |
 |
Cortexyme
CRTX
|
20.8 M | - | -1.05 % | $ 67.1 M | USA |
 |
Cellectar Biosciences
CLRB
|
9.56 M | $ 3.62 | -4.86 % | $ 44.2 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
83.5 M | - | - | $ 2.18 B | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
172 M | $ 11.45 | 0.09 % | $ 741 M | USA |
 |
BioNTech SE
BNTX
|
9.76 B | $ 94.91 | -1.14 % | $ 27.2 B |  Germany |
 |
Eloxx Pharmaceuticals
ELOX
|
19.2 M | - | -5.68 % | $ 8.28 M | USA |
 |
Acer Therapeutics
ACER
|
2.33 M | - | 2.71 % | $ 14 M | USA |
 |
Enochian Biosciences
ENOB
|
92.7 K | - | - | $ 40.5 M | USA |
 |
Acorda Therapeutics
ACOR
|
30 M | - | -24.86 % | $ 820 K | USA |